Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid Metabolic Labeling to Study Site- and Lipid-Specific Long-Chain <i>S</i>-Acylation Dynamics.

ACS chemical biology·2026
Same author

Quantitative analysis of S-acylation.

Methods in enzymology·2026
Same author

Proteomic profiling of colorectal liver metastases reveals histopathological response-specific molecular signatures of chemotherapy efficacy.

Journal of translational medicine·2026
Same author

Catalysis of Native Chemical Ligation and Expressed Protein Ligation by Alkylselenols.

JACS Au·2025
Same author

Different chains for different gains: How acyl chain diversity shapes S-acylated protein function.

Progress in lipid research·2025
Same author

Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer.

Science signaling·2025

Related Experiment Video

Updated: May 11, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Gunther Zimmermann1, Björn Papke, Shehab Ismail

  • 1Department of Chemical Biology, Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany.

Nature
|May 24, 2013
PubMed
Summary

Researchers developed small molecules that disrupt the KRAS-PDEδ interaction, offering a new strategy to inhibit oncogenic RAS signaling and suppress pancreatic cancer cell proliferation.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS is a key target in cancer drug discovery, but direct inhibition has proven challenging.
  • The prenyl-binding protein PDEδ regulates KRAS localization and signaling by controlling its diffusion.
  • Altering KRAS localization is a potential strategy to suppress oncogenic RAS signaling.

Purpose of the Study:

  • To investigate small molecules that interfere with the KRAS-PDEδ interaction.
  • To explore a novel approach for suppressing oncogenic RAS signaling by targeting KRAS localization.
  • To develop inhibitors of the KRAS-PDEδ interaction for potential anticancer therapies.

Main Methods:

  • Biochemical screening to identify inhibitors of the KRAS-PDEδ interaction.
  • Structure-based drug design for hit optimization.
  • Assays to evaluate inhibition of oncogenic RAS signaling and cancer cell proliferation in vitro and in vivo.

Main Results:

  • Identification of small molecules that selectively bind to PDEδ with nanomolar affinity.
  • Demonstration that these inhibitors disrupt the KRAS-PDEδ interaction.
  • Suppression of oncogenic RAS signaling and proliferation of KRAS-dependent pancreatic cancer cells.

Conclusions:

  • Targeting the KRAS-PDEδ interaction with small molecules is a viable strategy for suppressing oncogenic RAS signaling.
  • Inhibitors of the KRAS-PDEδ interaction show potential for treating KRAS-dependent cancers, particularly pancreatic ductal adenocarcinoma.
  • This approach offers a novel avenue for anticancer drug discovery efforts targeting KRAS.